{"entity":{"id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","aka":[],"tldr":"CD19 t-haNK is an experimental cell therapy whose type is not stated from ImmunityBio in phase 2 trials for hodgkin lymphoma, aimed at CD19.","summary":"CD19 t-haNK is a cell therapy whose type is not stated developed by ImmunityBio. Its target is CD19 (the sponsor names CD19). The sponsor states: CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab. ClinicalTrials.gov describes the intervention as: N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07125872, plans to enrol 20 participants with primary completion expected 2027-05-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of CD19 t-haNK","url":"https://clinicaltrials.gov/search?intr=CD19%20t-haNK"},{"label":"Sponsor pipeline page","url":"https://www.immunitybio.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07125872"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"cell therapy (type not stated)","mechanism":"CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cd19-t-hank/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}],"trial":[{"id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","route":"/trials/nct07125872/"}]}}